ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
Dow Jones
38,686.32
1.51%
Brent Oil
81.295
0.00%
Bitcoin
67,721.33
-0.01%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Inhibikase Therapeutics Inc (IKT)

  7. Inhibikase Therapeutics Inc (IKT) News

IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IKT
DateTimeSourceHeadlineSymbolCompany
05/22/20248:55AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
05/20/20248:55AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
05/20/20248:01AMGlobeNewswire Inc.Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionNASDAQ:IKTInhibikase Therapeutics Inc
05/20/20247:09AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
05/15/20248:00PMGlobeNewswire Inc.Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
05/15/20245:04PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
05/15/20248:45AMGlobeNewswire Inc.Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementNASDAQ:IKTInhibikase Therapeutics Inc
05/15/20247:56AMEdgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IKTInhibikase Therapeutics Inc
05/09/20242:41PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
05/09/20248:00AMGlobeNewswire Inc.Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
04/18/20244:30PMGlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
04/03/20248:05AMGlobeNewswire Inc.Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
03/27/20244:15PMGlobeNewswire Inc.Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityNASDAQ:IKTInhibikase Therapeutics Inc
03/07/20248:30AMGlobeNewswire Inc.Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersNASDAQ:IKTInhibikase Therapeutics Inc
02/28/20244:05PMGlobeNewswire Inc.Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
02/07/20247:59AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
02/07/20247:55AMGlobeNewswire Inc.Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersNASDAQ:IKTInhibikase Therapeutics Inc
02/01/20244:49PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
02/01/20244:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
01/29/20249:05AMGlobeNewswire Inc.Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with RisvodetinibNASDAQ:IKTInhibikase Therapeutics Inc
01/16/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
01/16/20244:05PMGlobeNewswire Inc.Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph FrattaroliNASDAQ:IKTInhibikase Therapeutics Inc
12/19/20238:30AMGlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
12/04/20238:35AMGlobeNewswire Inc.Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
11/14/20234:30PMGlobeNewswire Inc.Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
11/07/20239:28AMGlobeNewswire Inc.Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023NASDAQ:IKTInhibikase Therapeutics Inc
11/07/20238:00AMGlobeNewswire Inc.Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023NASDAQ:IKTInhibikase Therapeutics Inc
10/16/20235:24PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
10/16/20237:00AMGlobeNewswire Inc.Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing EnrollmentNASDAQ:IKTInhibikase Therapeutics Inc
10/04/20238:30AMGlobeNewswire Inc.Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System AtrophyNASDAQ:IKTInhibikase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IKT

Your Recent History

USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
FNMA
Fannie Mae (QB)
USOTC
ENZC
Enzolytics (PK)
USOTC
ERHE
ERHC Energy (CE)
NASDAQ
DJT
Trump Media and Technology
USOTC
CIVX
CTR Investments and Cons... (CE)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
RNVA
Rennova Health (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
BLEG
Branded Legacy (PK)
NASDAQ
LWLG
Lightwave Logic
NASDAQ
COOP
Mr Cooper
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
RDGL
Vivos (QB)
USOTC
DBMM
Digital Brand Media and ... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved